Absorption, metabolism, and excretion of [(14)C]ponatinib after a single oral dose in humans

Por Ye, Yihua E., Woodward, Caroline N., Narasimhan, Narayana I.
Publicado no Cancer Chemother Pharmacol (2017)

Phase II Dose Selection for Alpha Synuclein–Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain

Por Kuchimanchi, Mita, Monine, Michael, Kandadi Muralidharan, Kumar, Woodward, Caroline, Penner, Natalia
Publicado no CPT Pharmacometrics Syst Pharmacol (2020)

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Por Sydor, Jens R., Normant, Emmanuel, Pien, Christine S., Porter, James R., Ge, Jie, Grenier, Louis, Pak, Roger H., Ali, Janid A., Dembski, Marlene S., Hudak, Jebecka, Patterson, Jon, Penders, Courtney, Pink, Melissa, Read, Margaret A., Sang, Jim, Woodward, Caroline, Zhang, Yilong, Grayzel, David S., Wright, Jim, Barrett, John A., Palombella, Vito J., Adams, Julian, Tong, Jeffrey K.
Publicado em 2006